Pattara Wiromrat1, Petter Bjornstad1,2, Carissa Vinovskis1, Linh T Chung1, Carlos Roncal2, Laura Pyle1,3, Miguel A Lanaspa2, Richard J Johnson2, David Z Cherney4, Tyler K Reznick-Lipina5, Franziska Bishop5, David M Maahs6,7, Raj Paul Wadwa5. 1. Section of Endocrinology, Department of Pediatrics, University of Colorado Denver School of Medicine, Aurora, Colorado. 2. Section of Nephrology, Department of Medicine, University of Colorado Denver School of Medicine, Aurora, Colorado. 3. Barbara Davis Center for Childhood Diabetes, University of Colorado Denver School of Medicine, Aurora, Colorado. 4. Department of Biostatistics and Informatics, University of Colorado Denver School of Public Health, Aurora, Colorado. 5. Department of Nephrology, University of Toronto School of Medicine, Toronto, Ontario, Canada. 6. Section of Endocrinology, Department of Pediatrics, Stanford University School of Medicine, Stanford, California. 7. Stanford Diabetes Research Center, Stanford University School of Medicine, Stanford, California.
Abstract
OBJECTIVE: We sought to evaluate copeptin concentrations in adolescents with and without type 1 diabetes (T1D) and examine the associations between copeptin and measures of arterial stiffness and kidney dysfunction. RESEARCH DESIGN AND METHODS: This analysis included 169 adolescents with T1D (12-19 years of age, 59% girls, mean HbA1c 9.0 ± 1.5% and diabetes duration of 8.6 ± 2.9 years), in addition to 61 controls without T1D. Arterial stiffness including carotid-femoral pulse wave velocity (CF-PWV), carotid-radial PWV (CR-PWV), augmentation index normalized to heart rate of 75 bpm (AIx@HR75), and brachial artery distensibility (BAD). Serum copeptin, urinary albumin-to-creatinine ratio (UACR), and estimated glomerular filtration rate (eGFR) by serum creatinine and cystatin C were also assessed. RESULTS: Compared to controls, adolescents with T1D had higher median (Q1-Q3) copeptin (7.5 [5.2-11.3] vs 6.4 [4.8-8.3] pmol/L, P = .01), mean ± SD eGFR (121 ± 23 vs 112 ± 16 mL/min/1.73m2 , P = .002) and lower BAD (7.1 ± 1.3 vs 7.2 ± 1.2%, P = .02). Adolescents with T1D in the in high tertile copeptin group (>9.1 pmol/L) had higher AIx@HR75 (10.7 ± 1.2 vs 5 ± 1.2, P = .001), CR-PWV (5.30 ± 1.0 vs 5.18 ± 1.0 m/s, P = .04), and UACR (12 ± 1 vs 8 ± 1 mg/g, P = .025) compared to those in low tertile (<5.8 pmol/L) after adjusting for age, sex, and eGFR. Copeptin inversely associated with CF-PWV independent of age, sex, eGFR, SBP, and HbA1c in T1D adolescents. CONCLUSIONS: Our data demonstrate that elevated copeptin was associated with worse arterial stiffness in adolescents with T1D. These findings suggest that copeptin could improve CVD risk stratification in adolescents with T1D.
OBJECTIVE: We sought to evaluate copeptin concentrations in adolescents with and without type 1 diabetes (T1D) and examine the associations between copeptin and measures of arterial stiffness and kidney dysfunction. RESEARCH DESIGN AND METHODS: This analysis included 169 adolescents with T1D (12-19 years of age, 59% girls, mean HbA1c 9.0 ± 1.5% and diabetes duration of 8.6 ± 2.9 years), in addition to 61 controls without T1D. Arterial stiffness including carotid-femoral pulse wave velocity (CF-PWV), carotid-radial PWV (CR-PWV), augmentation index normalized to heart rate of 75 bpm (AIx@HR75), and brachial artery distensibility (BAD). Serum copeptin, urinary albumin-to-creatinine ratio (UACR), and estimated glomerular filtration rate (eGFR) by serum creatinine and cystatin C were also assessed. RESULTS: Compared to controls, adolescents with T1D had higher median (Q1-Q3) copeptin (7.5 [5.2-11.3] vs 6.4 [4.8-8.3] pmol/L, P = .01), mean ± SD eGFR (121 ± 23 vs 112 ± 16 mL/min/1.73m2 , P = .002) and lower BAD (7.1 ± 1.3 vs 7.2 ± 1.2%, P = .02). Adolescents with T1D in the in high tertile copeptin group (>9.1 pmol/L) had higher AIx@HR75 (10.7 ± 1.2 vs 5 ± 1.2, P = .001), CR-PWV (5.30 ± 1.0 vs 5.18 ± 1.0 m/s, P = .04), and UACR (12 ± 1 vs 8 ± 1 mg/g, P = .025) compared to those in low tertile (<5.8 pmol/L) after adjusting for age, sex, and eGFR. Copeptin inversely associated with CF-PWV independent of age, sex, eGFR, SBP, and HbA1c in T1D adolescents. CONCLUSIONS: Our data demonstrate that elevated copeptin was associated with worse arterial stiffness in adolescents with T1D. These findings suggest that copeptin could improve CVD risk stratification in adolescents with T1D.
Authors: Claudia A Bertuccio; Fernando R Ibarra; Jorge E Toledo; Elvira E Arrizurieta; Rodolfo S Martin Journal: Am J Physiol Renal Physiol Date: 2002-02
Authors: Wiebke Fenske; Stefan Störk; Anne Blechschmidt; Sebastian G K Maier; Nils G Morgenthaler; Bruno Allolio Journal: J Clin Endocrinol Metab Date: 2008-11-04 Impact factor: 5.958
Authors: Petter Bjornstad; Richard J Johnson; Janet K Snell-Bergeon; Laura Pyle; Asa Davis; Nicole Foster; David Z Cherney; David M Maahs Journal: J Diabetes Complications Date: 2016-12-07 Impact factor: 2.852
Authors: Amy S Shah; R Paul Wadwa; Dana Dabelea; Richard F Hamman; Ralph D'Agostino; Santica Marcovina; Stephen R Daniels; Lawrence M Dolan; Nora F Fino; Elaine M Urbina Journal: Pediatr Diabetes Date: 2015-04-24 Impact factor: 4.866
Authors: Melissa J Johnson; Kalie L Tommerdahl; Carissa Vinovskis; Sushrut Waikar; Trenton Reinicke; Chirag R Parikh; Wassim Obeid; Robert G Nelson; Daniel H van Raalte; Laura Pyle; Kristen J Nadeau; Petter Bjornstad Journal: Pediatr Nephrol Date: 2022-03-14 Impact factor: 3.651